Related Experiment Video
Updated: Jan 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeted Inhibition in Pediatric MET and ALK-Altered Hemispheric Gliomas: Objective Responses Followed by Treatment
David Wilson1,2,3, Sateesh Jayappa3,4, Lora Parker3
1Department of Pediatrics, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72223, USA.
Pediatric high-grade gliomas (pHGGs) with targetable gene alterations can initially respond to targeted therapies. However, resistance often develops, necessitating further molecular analysis for effective treatment adjustments.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Molecular targeted therapy
Background:
- Pediatric-type diffuse high-grade gliomas (pHGGs) have poor prognoses.
- Specific genetic alterations (ROS1, ALK, MET, NTRK) are found in some pHGGs.
- The efficacy of targeted agents in pHGGs remains under investigation.
More Related Videos
12:55Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacokinetics in Pediatric Patients: Drug Metabolism